Introduction: the evolving role of bisphosphonate therapy in multiple myeloma.
Raje
N
N
Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Anderson
K C
KC
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001862:Bone Resorption / Q000209:etiology / Q000517:prevention & control; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D015850:Interleukin-6 / Q000096:biosynthesis; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D010010:Osteoclasts / Q000502:physiology; D000093242:Interleukin-6 Inhibitors
D000970:Antineoplastic Agents; D004164:Diphosphonates; D015850:Interleukin-6; D000093242:Interleukin-6 Inhibitors